X

Trial Profile

A Multicentre Randomised Phase III Trial Comparing Pembrolizumab Versus Standard Chemotherapy for Advanced Pre-treated Malignant Pleural Mesothelioma

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 19 Aug 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary) ; Gemcitabine; Vinorelbine; Vinorelbine
Indications Malignant-mesothelioma
Focus Therapeutic Use
Acronyms PROMISE-meso

Most Recent Events

31 Dec 2021 Status changed from active, no longer recruiting to completed.
08 Feb 2021 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.
22 Sep 2020 Results (n=144; data cut off: 20 February 2019) published in the Annals of Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com